At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 80 years
- ✓ECOG performance status 0 or 1
- ✓No prior lung cancer surgery
- ✓Resectable cT1N0M0 tumors with CTR>0.5 in apical segment
- ✕Not cT1N0M0 stage
- ✕Nodules not in apical segment or CTR≤0.5
- ✕Pre-invasive adenocarcinoma, lepidic predominant, or non-adenocarcinoma
- ✕Prior lung cancer surgery
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06031246Phase 3RecruitingMonitorUpdated 33mo ago · Completion was 5mo agoSelective Lymph Node Dissection for cT1N0M0 Invasive Non-small Cell Lung Cancer With CTR>0.5 Located in the Apical Segment: a Single-arm, Multi-center, Phase III Trial
In Brief
A Phase 3 clinical trial evaluating Selective Lymph Node Dissection for Lung Adenocarcinoma and Lymph Node Metastasis. Currently recruiting, targeting 634 participants across 1 site.
Signals
Detailed Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1018. The goal of this clinical trial is to confirm the theraputic effect of selective lymph node dissection for cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment. The main questions it aims to answer are: The 5-year overall survival of patients having cT1N0M0 invasive non-small cell lung cancer with CTR\>0.5 located in the apical segment; The post-operative lymph node metastasis and recurrence-free survival. Participants will receive selective lymph node dissection as the surgical procedure.
Study Details
Timeline
Interventions
For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected